ADHD Stimulants: Double-Digit Hikes Far Outpace Other Categories
Skimming this quarter’s NADAC update, one outlier leaps off the spreadsheet: average prices for amphetamine mixed salts (immediate-release), the standard-bearer of ADHD therapy, jumped 18% quarter-over-quarter. For reference, a leading 30mg NDC climbed from $1.13 to $1.34 per unit. This far surpasses basic inflation and even the drug’s own recent price history.
And mixed salts aren’t alone. Methylphenidate ER generics followed suit, clocking a 12% average increase, with some NDCs logging double-digit spikes in just a single month. All this hits pharmacy buyers, chains and independents alike, hard, since most payer reimbursement remains pegged to NADAC and resets frequently. For specialty pharmacies, margin pressure is essentially instantaneous.
What’s fueling this? Multiple wholesalers are pointing fingers at ongoing active pharmaceutical ingredient (API) supply constraints, particularly out of India and China. At the same time, several mid-tier manufacturers have filed for price hikes, citing increased input costs and persistent shortages of key actives. Meanwhile, demand remains ravenous: among commercially insured patients, utilization is the highest it’s ever been, with claims volumes up nearly 7% over the past year.
For plan sponsors and employers, the impact is direct: elevated ADHD drug spend is locked in for at least another quarter, especially if API supply bottlenecks continue. Anyone needing a closer look at how that trickles through formulary coverage or employer costs should keep an eye on the RxBenefits.ai portal, which updates ADHD trend projections weekly.
Diabetes Pricing Swings: GLP-1s Defy Gravity Amid Metformin’s Slide
Diabetes drug pricing tells a story of extremes right now. GLP-1s like semaglutide (Ozempic, Wegovy) barely flinched in the face of the latest NADAC resets, while metformin IR generics, on the other hand, saw their prices tumble. Notably, a major metformin NDC dropped 13%, the steepest quarterly cut since 2021. The average NADAC there now sits at $0.05 per tablet, down from $0.057 just months ago.
Meanwhile, GLP-1s keep climbing: semaglutide posted a 4% quarter-over-quarter uptick for its most-dispensed strengths. But that number doesn’t do justice to the real behind-the-scenes costs. Payer rebates and PBM contracts mean true net prices often land well below NADAC. For anyone who wants a running tally, RxPBM.ai tracks GLP-1 spreads and manufacturer discounts in near-real time.
The metformin drops are squeezing pharmacies, particularly those reliant on NADAC-tied reimbursement models. While insurers eye the chance to lower spend for plan sponsors, indie pharmacies bear the brunt, with these declines coming right off the top line. Stack the higher GLP-1 costs on top, and you have a pressure cooker for buyers lacking PBM leverage.
Competitive Fire Drills: Pain, Antidepressant, and Antibiotic Generics Plunge
Across the generics landscape, some of the most-used products are buckling under the weight of new entrants. Take sertraline 50mg, a linchpin in the antidepressant market, average NADAC fell 9% to just $0.07 per tablet. Ibuprofen 800mg followed, plunging nearly 11% after two more U.S. manufacturers joined the fray.
Amoxicillin suspension, a go-to for pediatric antibiotic scripts, finally saw its winter shortage-driven price spike reverse. With supply catching up and post-respiratory season demand easing, average price dropped 12%. Pharmacies that stocked up at peak prices are stuck with high-cost inventory, facing negative margins as reimbursement lags behind actual market prices. NADAC’s update cycle ensures some pharmacies endure weeks of below-cost fills before the adjustment comes. A rough ride if you mistime your purchases.
What’s really shifted is just how fast these prices are falling. In the past, this level of generic price erosion took half a year or more. Now, it’s happening inside a single quarter, sometimes even within one monthly NADAC update. PBMs with real-time repricing tech (increasingly standard, per RxPBM.ai) are able to capture those savings almost immediately. But for retail and specialty pharmacies, the system is less forgiving, slower to reward, quick to penalize.
Stability on the Surface: Respiratory and Biologics Pricing Behind the Curtain
For most branded inhalers and biologics, NADAC barely budged this quarter, typically less than 2% up or down. But that headline “stability” is misleading, more illusion than fact. Underneath, rebate negotiations, specialty pharmacy carve-outs, and off-cycle formulary shifts are rewriting the net price landscape in ways NADAC numbers never reveal.
Humira stands as a prime example. Its NADAC only slipped 1.1% this quarter, hovering around $6,400 per syringe. But with biosimilars flooding in, the PBM rebate game has dramatically altered net costs, big payers now report Humira spend down by 20% or more, based on recent RxNews.ai reporting. Pharmacies, though, are trapped: reimbursement remains anchored to sticker price, and margins don’t budge, even as net drug costs plummet for everyone else. Strange system, honestly.
Asthma inhalers, think fluticasone-salmeterol, barely registered a blip on NADAC (just 0.5% movement). On the ground? There’s still an all-out contracting war, with payers and manufacturers sparring over rebates and discounts. For now, retail pharmacies coast along on thin, flat margins, while payers work feverishly to extract every penny in off-invoice savings.
Where the Money Shifts Next
The latest NADAC numbers, once again, map out a split market. ADHD and diabetes categories, driven by unyielding demand and ongoing supply headaches, continue to climb, hitting both payers and pharmacies with higher costs. Meanwhile, generics for pain, psych, and infectious diseases are seeing the swiftest price drops in recent memory; plan sponsors get relief, but pharmacy margins keep getting thinner.
Keep close tabs on API supply for stimulants, watch for fresh generic players in crowded spaces, and never trust stability in branded categories, rebates and contracting battles still redraw the map behind the scenes. NADAC’s data tells a lot, but never the whole story. And honestly, sometimes it feels like the moving pieces outnumber the answers.
